Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) is anticipated to announce its Q1 2025 earnings results before the market opens on Monday, May 12th. Analysts expect Capricor Therapeutics to post earnings of ($0.33) per share and revenue of $3.16 million for the quarter.
Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.31) by $0.15. The company had revenue of $11.13 million during the quarter, compared to analysts' expectations of $9.87 million. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. On average, analysts expect Capricor Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Capricor Therapeutics Price Performance
CAPR opened at $11.86 on Monday. The stock's 50 day simple moving average is $11.84 and its 200 day simple moving average is $14.58. The stock has a market cap of $541.73 million, a P/E ratio of -11.19 and a beta of 0.85. Capricor Therapeutics has a 1-year low of $3.52 and a 1-year high of $23.40.
Wall Street Analyst Weigh In
Several equities research analysts recently commented on CAPR shares. HC Wainwright reiterated a "buy" rating and issued a $77.00 price objective on shares of Capricor Therapeutics in a research report on Monday, March 17th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $30.00 price target on shares of Capricor Therapeutics in a report on Thursday, March 20th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $34.50.
Check Out Our Latest Analysis on Capricor Therapeutics
About Capricor Therapeutics
(
Get Free Report)
Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Capricor Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.
While Capricor Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
